Introduction
In the UK, there is an estimated incidence of 70,000 hip fractures per year with reported annual hip fracture healthcare costs exceeding 2 billion pounds (1, 2) . Hip fracture patients are often elderly with a high risk of perioperative morbidity and mortality related to their age and comorbidities (3). Mortality rates have been reported as high as 10% and 30% at 30 days and 1 year respectively (4).
Although, TXA is known to minimise blood loss in other surgical disciplines, the role of TXA in hip fracture surgery remains uncertain due to its potential prothrombotic effect (12) . Numerous studies have evaluated the role of TXA in hip fracture care, but there remains a lack of higher level evidence on TXA use in operative hip fracture management. The objective of this meta-analysis of randomised and nonrandomised controlled trials was to investigate the efficacy of TXA in hip fracture surgery on operative and total blood loss, allogenic blood transfusion requirements and venous thromboembolic (VTE) event incidence.
Materials and methods

Study design
This review and meta-analysis was conducted using PRIS-MA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (13) and in line with recommendations from the Cochrane Collaboration and Quality of Reporting of Meta-Analyses (QUORUM) guidelines (14) .
Search methodology
A systematic computerised literature search of online data-bases including PubMed, Medline, Embase, Cochrane and Controlled Trials Register, Ovid, Trip and Google to search for articles was conducted and completed by 2 Independent authors. The exploded Medical Subject Headings were used for the initial literature search were 'Hip', 'Fracture', 'Tranexamic acid', 'Hemiarthroplasty', 'Total Hip Replacement', 'Open Reduction and Internal Fixation', 'Dynamic Hip Screw', 'Intramedullary Nail' and 'Blood Loss'. All articles published before July 01, 2016 were included.
Inclusion and exclusion criteria
A standardised checklist was developed by authors to analyse each paper for potential inclusion and exclusions. Studies were included if they met the following criteria: (i) participants undergoing hip fracture surgery; (ii) assigned patients to the treatment group who received intravenous (IV) TXA and control patients who received a placebo or no treatment; (iii) both groups reported 1 of the following outcomes: blood loss, receipt of allogenic transfusion, number of blood transfusions per patient, number of patients with a VTE event. Studies were excluded if they were non-English language, compared nonintravenous administration routes of TXA or not part of complete articles.
Study selection
The searches were then distributed to 2 independent authors and reviewed for similarities in study design, methodology, patient demographics and outcomes measured according to the checklist. The authors independently evaluated the eligibility of all studies retrieved from the databases based on this predetermined selection criteria. All abstracts were reviewed to exclude irrelevant articles. Bibliographies of appropriate articles were also reviewed to identify additional papers. Any sources of ambiguity were discussed and scrutinised by the senior author. References and data for all included studies were carefully checked to ensure that no overlapping or replication of data was presented.
Data abstraction
Data extrapolated from the included studies was entered by 2 independent authors and any discrepancies were resolved by the senior author. The following data were collected from relevant papers; study design, sample size, type of surgery, TXA dose, VTE prophylaxis, VTE screening, type of anaesthesia, blood transfusion criteria, methods of measuring blood loss, patient factors (gender, age, weight), total blood loss, perioperative blood loss, number of allogenic blood transfusions, duration of surgery, preoperative haemoglobin level, postoperative haemoglobin level, number of recorded VTE events.
Quality assessment
A qualitative analysis of the randomised control studies was conducted using the mixed methods and assessment tool (MMAT) (15) . This is a validated assessment tool utilised in systematic reviews and meta-analysis to appraise the methodology of studies (16) . Using this tool, study quality for each article was classified as weak (≤0.50), moderate-weak (0.51 to 0.65), moderate-strong (0.66 to 0.79), or strong (≥0.80) in terms of study quality.
A risk of bias assessment for individual studies was conducted by 2 independent reviewers using the Cochrane collaboration's risk of bias tool for randomised control trials (RCTs) and the risk of bias in nonrandomised studies -of interventions (ROBINS-I) tool for observational studies (17) (18) (19) .
Discrepancies in risk bias assessment between reviewers were discussed and scrutinised by the senior author.
Statistical analysis
All analysis was conducted using Review Manager Version 5 (The Cochrane Collaboration, Software Update).
For continuous data, such as blood loss, mean ± standard deviation (SD) was used to calculate the weighted mean difference (WMD) and 95% confidence interval (CI). For dichotomous data, relative risk (RR) and 95% CI were applied.
OR represents the odds of an adverse event occurring in the TXA group compared with the control group. An OR of <1 favoured the TXA group. The point estimate of the OR was considered statistically significant at the p<0.05 level, if the 95% CI did not include the value 1.
For continuous variables, the OR was calculated with the Mantle-Haenszel chi-square method using a random effects meta-analytical technique. The random effect model is particularly suitable for surgical research, as it assumes that there is natural variation between the studies, and the calculated ORs thus have a more conservative value. For continuous variables, e.g. time, statistical analysis was carried out using weighted mean difference (WMD) at the summary statistic. WMD of a negative value favoured the TXA group. For studies that presented continuous data as median and/ or range values, the standard deviation (SD) was calculated using statistical algorithms (20) .
Results
Characteristics of included studies
Our initial search strategy identified 264 potentially relevant citations (Fig. 1) . After careful evaluation, 248 citations were excluded following title and abstract screening. The full publications were retrieved for the remainder and a further 8 citations were excluded following subsequent scrutiny according to the inclusion and exclusion criteria. The remaining 8 studies were included in the systematic review and metaanalysis, leaving 6 randomised control trials (21) (22) (23) (24) (25) , and 2 cohort studies (26, 27) (Tab. I).
All studies were present after 2007 and compared use of IV TXA with normal saline. The majority were small studies with between 40 and 271 participants providing a total number of 338 TXA patients and 448 placebo patients. Further details of the study characteristics are presented in Table I .
Quality assessment
Only quantitative randomised controlled trials and quantitative nonrandomised components of the MMAT were utilised in this study. Quality assessment with the MMAT identified 6 strong studies (21-23, 25, 26, 28) with a score of 4, 1 moderate-strong study with a score of 3 (27) and 1 weak study with a score of 2 (24) (Tab. I). In the randomised control studies, various methods of randomisation were used including opaque sealed envelopes (23, 25) , random number techniques (22) , computer generated random number table (28) and stratified sampling technique with computer generated randomisation (21) . 1 study did not mention all baseline differences between the control and intervention group and was assessed as a moderate to strong study as a result rather than a strong study (27) . 1 study did not specify the method of randomisation or the allocation concealment and was consequently assessed as a weak study (24) .
A risk of bias assessment is presented in Table II . The risk of bias assessment across studies varied between different outcomes. There was a low risk of bias seen across studies for total blood loss and perioperative blood loss analysis. An unclear risk of bias across studies was present with duration of surgery analysis and a high risk of bias across studies was noted for allogenic blood transfusion requirements, post-operative haemoglobin level and postoperative VTE incidence analysis.
Total blood loss
5 studies provided usable information on the effect of IV TXA following hip fracture surgery on total blood loss (21, 22, 24, 25, 27) , which included assessment of combined blood loss during the operative and post-operative period following TXA administration. TXA led to a reduction in the total blood loss following hip fracture surgery with a calculated overall mean reduction of 442.90 mls (95% CI, 426.48-459.31; p<0.00001) (Fig. 2) .
Perioperative blood loss
4 studies provided adequate information on the effect of TXA on perioperative blood loss following hip fracture surgery (21, 22, 25, 27) , which included the assessment of blood loss during the operative procedure. TXA led to a reduction in perioperative blood loss following hip fracture surgery. There was a mean reduction of 88.52 mls (95% CI, 59.88-117.22; p<0.00001) (Fig. 3 ).
Blood transfusion requirements
Number of required allogenic blood transfusions following hip fracture surgery was assessed in all 8 studies (21-28). In total, 171 blood transfusions were given to 448 patients in the control group and 88 transfusions were given to 338 patients in the TXA group. TXA use had demonstrated a statistically significant decrease in the need for allogenic blood transfusion (OR 0.37; 95% CI, 0.26-0.53; p<0.00001) (Fig. 4) .
Duration of surgery
5 studies provided usable information on the duration of surgery (21, 23, 24, 27, 28) . There was no significant difference or advantage seen in the duration of surgery with the use of TXA compared with patients who had placebo (p>0.06) (Fig. 5) .
Postoperative haemoglobin level
6 studies provided usable data on the effect of TXA on postoperative haemoglobin levels following hip fracture surgery (22) (23) (24) (26) (27) (28) . There was a statistically reduction in haemoglobin level seen in patients who had TXA compared with those who had placebo (p = 0.013) (Fig. 6 ).
Postoperative venous thromboembolic events
7 Studies assessed the impact of TXA on the incidence of VTE events (21-26, 28 ). 13 VTE events occurred amongst 271 patients in the TXA group and 10 VTE events occurred amongst 379 patients in the placebo group. The use of TXA and a causal link was not seen (OR 1.59; 95% CI, 0.67-3.75; p>0.29) (Fig. 7) .
Discussion
Despite extensive evidence supporting TXA use in total hip arthroplasty (29, 30) , there is a lack of high quality evidence and clinical guidance regarding the role of TXA in hip fracture surgery. Coupled with reduced costs and potent efficacy to minimise blood loss, TXA has gained popularity as a pharmaceutical measure to minimise intraoperative bleeding and has been shown to be more effective than other closely related therapeutic agents (31).
A previous meta-analysis and systematic review on the efficacy of TXA in hip fracture surgery by Farrow et al (32) has been conducted, but there are differences between this and our current review. Our review includes an additional study, and excluded topical use of TXA.
The most significant finding from our meta-analysis was the efficacy of TXA for minimising total blood loss and reducing the need for allogenic blood transfusion. Despite statistical significance, large variations of mean total blood loss differences between the TXA and control group were noted. Sources of heterogeneity included sample size variation, diverse patient characteristics, differing inclusion and exclusion criteria, mode of anaesthesia and varied outcome measurement protocols. Zufferey et al (21) calculated blood loss using pre-and postoperative haemoglobin measurements in Fig. 7 -Venous thromboembolic events. Forest plot diagram showing the effect of tranexamic acid (TXA) on venous thromboembolic incidence. The black diamond signifies the mean difference is in favour of control however, this is not significant. A black square is given to dichotomous outcomes. The size of each square depends on the weight of each study. contrast to Tengberg et al (25) who calculated blood loss using the Nadler formula, pre-and postoperative haemoglobin levels and number of transfusions required. Shiva et al (27) , Sadeghi et al (22) and Emara et al (24) used more direct measurements of measuring blood loss including measurement of perioperative suction drain volumes, swab weights and postoperative indwelling drain measurements.
Other sources of heterogeneity included varying fracture configurations and fracture management. Previous comparison of fracture configurations in the literature reported the highest need for blood transfusions in patients with extracapsular hip fractures (33) . However, a meta-analysis conducted by Wang et al (34) comparing hip fracture fixation and replacement methods for different fracture types reported higher blood losses in patients managed with arthroplasty. With respect to extracapsular fracture management, the current evidence comparing intramedullary and extramedullary fixation remains inconclusive with increased (35) , reduced (36) , and no blood loss differences reported (37) .
Analysis of pre-and postoperative haemoglobin level differences demonstrated statistically significant postoperative haemoglobin level reduction with TXA use (p = 0.013).
However, our analysis was statistically limited by exclusive use of absolute mean pre-and postoperative haemoglobin levels with exclusion of standard deviation values.
The need for allogenic blood transfusions was minimised with the use of TXA (p<0.00001). However, various transfusion triggers were utilised between studies. Blood transfusion thresholds varied from Hb<70 g/L (28), to Hb <100 g/L (21) and may have led to underrepresentation of required allogenic blood transfusions between the TXA and placebo groups.
In our meta-analysis, no significant increase in VTE risk was seen with the use of TXA however, this varied between studies included in the analysis. Zufferey et al (21) and Emara et al (24) described an increase in VTE risk with TXA use concluding that this may be the result of an TXA induced hypercoagulable state as suggested in other studies (23, 38) . Only the findings in the latter study were significant however. Mohib et al (28) , Vijay et al (23) , and Sadeghi et al (22) , reflected the findings from this current study and described no significant difference in VTE events between the TXA and control group whilst Lee et al (26) , and Tengberg et al (25) , described a nonsignificant VTE risk reduction in the TXA group compared with the control group. However, the physiology of hip fracture patients is modified as a result of surgical and trauma induced fibrinolytic system activation, which may reduce the hypercoagulable effects of TXA resulting in an overall reduced VTE risk. The nonsignificant result in this study may have resulted from heterogeneous VTE detection methods. Zufferey et al (21) conducted daily clinical assessments and routine ultrasound screening between day 7 and day 10. They included both asymptomatic and symptomatic VTE events, which have led to over diagnosis of VTE events in contrast to the remaining 6 studies (22-24, 26, 28, 39) , which used clinical assessments and indicated radiological diagnostic methods, which may have led to missed VTE events (22-24, 26, 39) .
We acknowledge potential limitations in this study. The inclusion of non-randomised studies may have introduced a source of selection bias. Although included studies were mostly of good methodologic quality and design as evidenced by high MMAT scores, risk of bias assessment of individual studies and across studies demonstrated that most of the studies had either an unclear or serious risk of bias. This highlighted a weakness in the included studies which would limit the conclusions drawn from our analysis. From our extensive searches, only a few studies met the inclusion criteria suggesting there may be a publication bias present, which may have overestimated TXA clinical efficacy. Our study also observed inter-study variability which may have limited a meaningful sub-analysis of data.
Furthermore, our review and meta-analysis included studies which varied in type of anaesthesia used with some study protocols including either general or regional anaesthetic techniques. As different types of anaesthesia have been shown to influence the amount of blood loss in lower limb surgery, this may have been a confounding factor which affected our results (40) .
As heterogeneous doses and frequency of IV TXA administration were used between different studies, our meta-analysis could not conclude the optimum therapeutic TXA dose. Consequently, we suggest further work should be directed towards finding the optimum homogenous TXA dose required to minimise blood loss, allogenic blood transfusions and VTE incidence in hip fracture patients. In addition, our analysis did not include studies which used local or topical administration of TXA and we recommend further evaluation of different TXA administration routes in hip fracture surgery as significant differences have been demonstrated in elective hip and knee surgery (30) .
Conclusion
Our review has demonstrated the efficacy of IV TXA use in hip fracture care at the time of surgery and supports its use in minimising perioperative and total blood loss without significantly increasing venous thromboembolic risk. However, data is limited and we conclude that more homogeneous randomised control trials should be performed to provide more robust data on its use in hip fracture surgery.
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